Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04811469




Registration number
NCT04811469
Ethics application status
Date submitted
16/08/2020
Date registered
23/03/2021
Date last updated
10/08/2022

Titles & IDs
Public title
Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of CBP-174 After Oral Administration
Secondary ID [1] 0 0
CBP-174AU001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy Adult Subjects 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - CBP-174
Treatment: Drugs - Placebo

Experimental: CBP-174 - CBP-174 oral solution

Experimental: Placebo - placebo oral solution


Treatment: Drugs: CBP-174
CBP-174 oral solution, given once

Treatment: Drugs: Placebo
Placebo oral solution, given once
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Incidence of adverse events and serious adverse events
Timepoint [1] 0 0
Up to 7 days post dosing
Primary outcome [2] 0 0
Severity of adverse events and serious adverse events
Timepoint [2] 0 0
Up to 7 days post dosing
Primary outcome [3] 0 0
Change in blood pressure
Timepoint [3] 0 0
Up to 7 days post dosing
Primary outcome [4] 0 0
Change in pulse rate
Timepoint [4] 0 0
Up to 7 days post dosing
Primary outcome [5] 0 0
Change in respiratory rate
Timepoint [5] 0 0
Up to 7 days post dosing
Primary outcome [6] 0 0
Change in tympanic temperature
Timepoint [6] 0 0
Up to 7 days post dosing
Primary outcome [7] 0 0
Clinically significant abnormality in physical examinations
Timepoint [7] 0 0
Up to 7 days post dosing
Primary outcome [8] 0 0
Clinically significant change in heart rate
Timepoint [8] 0 0
Up to 7 days post dosing
Primary outcome [9] 0 0
Clinically significant change in RR interval
Timepoint [9] 0 0
Up to 7 days post dosing
Primary outcome [10] 0 0
Clinically significant change in PR interval
Timepoint [10] 0 0
Up to 7 days post dosing
Primary outcome [11] 0 0
Clinically significant change in QRS complex
Timepoint [11] 0 0
Up to 7 days post dosing
Primary outcome [12] 0 0
Clinically significant change in QT interval
Timepoint [12] 0 0
Up to 7 days post dosing
Primary outcome [13] 0 0
Clinically significant change in Fridericia's Correction QT (QTcF) interval
Timepoint [13] 0 0
Up to 7 days post dosing
Primary outcome [14] 0 0
Clinically significant abnormal laboratory value in Total Protein (TB)
Timepoint [14] 0 0
Up to 7 days post dosing
Primary outcome [15] 0 0
Clinically significant abnormal laboratory value in Albumin (ALB)
Timepoint [15] 0 0
Up to 7 days post dosing
Primary outcome [16] 0 0
Clinically significant abnormal laboratory value in Alanine aminotransferase (ALT)
Timepoint [16] 0 0
Up to 7 days post dosing
Primary outcome [17] 0 0
Clinically significant abnormal laboratory value in Aspartate aminotransferase (AST)
Timepoint [17] 0 0
Up to 7 days post dosing
Primary outcome [18] 0 0
Clinically significant abnormal laboratory value in Alkaline phosphatase (ALP/AKP)
Timepoint [18] 0 0
Up to 7 days post dosing
Primary outcome [19] 0 0
Clinically significant abnormal laboratory value in Glutamyl transpeptidase
Timepoint [19] 0 0
Up to 7 days post dosing
Primary outcome [20] 0 0
Clinically significant abnormal laboratory value in Total bilirubin
Timepoint [20] 0 0
Up to 7 days post dosing
Primary outcome [21] 0 0
Clinically significant abnormal laboratory value in Direct Bilirubin
Timepoint [21] 0 0
Up to 7 days post dosing
Primary outcome [22] 0 0
Clinically significant abnormal laboratory value in Indirect Bilirubin
Timepoint [22] 0 0
Up to 7 days post dosing
Primary outcome [23] 0 0
Clinically significant abnormal laboratory value in Blood Glucose
Timepoint [23] 0 0
Up to 7 days post dosing
Primary outcome [24] 0 0
Clinically significant abnormal laboratory value in Blood Urea
Timepoint [24] 0 0
Up to 7 days post dosing
Primary outcome [25] 0 0
Clinically significant abnormal laboratory value in Blood Uric Acid
Timepoint [25] 0 0
Up to 7 days post dosing
Primary outcome [26] 0 0
Clinically significant abnormal laboratory value in Blood Creatinine
Timepoint [26] 0 0
Up to 7 days post dosing
Primary outcome [27] 0 0
Clinically significant abnormal laboratory value in Blood Creatine Kinase
Timepoint [27] 0 0
Up to 7 days post dosing
Primary outcome [28] 0 0
Clinically significant abnormal laboratory value in Blood Potassium
Timepoint [28] 0 0
Up to 7 days post dosing
Primary outcome [29] 0 0
Clinically significant abnormal laboratory value in Blood Sodium
Timepoint [29] 0 0
Up to 7 days post dosing
Primary outcome [30] 0 0
Clinically significant abnormal laboratory value in Blood Chloride
Timepoint [30] 0 0
Up to 7 days post dosing
Primary outcome [31] 0 0
Clinically significant abnormal laboratory value in Blood Calcium
Timepoint [31] 0 0
Up to 7 days post dosing
Primary outcome [32] 0 0
Clinically significant abnormal laboratory value in Blood Total Cholesterol
Timepoint [32] 0 0
Up to 7 days post dosing
Primary outcome [33] 0 0
Clinically significant abnormal laboratory value in Blood Triglycerides
Timepoint [33] 0 0
Up to 7 days post dosing
Primary outcome [34] 0 0
Clinically significant abnormal change in Leukocyte Count
Timepoint [34] 0 0
Up to 7 days post dosing
Primary outcome [35] 0 0
Clinically significant abnormal change in Neutrophil count
Timepoint [35] 0 0
Up to 7 days post dosing
Primary outcome [36] 0 0
Clinically significant abnormal change in Lymphocyte count
Timepoint [36] 0 0
Up to 7 days post dosing
Primary outcome [37] 0 0
Clinically significant abnormal change in Monocytes count
Timepoint [37] 0 0
Up to 7 days post dosing
Primary outcome [38] 0 0
Clinically significant abnormal change in Eosinophils count
Timepoint [38] 0 0
Up to 7 days post dosing
Primary outcome [39] 0 0
Clinically significant abnormal change in Basophil count
Timepoint [39] 0 0
Up to 7 days post dosing
Primary outcome [40] 0 0
Clinically significant abnormal change in percentage of Neutrophil
Timepoint [40] 0 0
Up to 7 days post dosing
Primary outcome [41] 0 0
Clinically significant abnormal change in percentage of Lymphocyte
Timepoint [41] 0 0
Up to 7 days post dosing
Primary outcome [42] 0 0
Clinically significant abnormal change in percentage of Monocytes
Timepoint [42] 0 0
Up to 7 days post dosing
Primary outcome [43] 0 0
Clinically significant abnormal change in percentage of Eosinophils
Timepoint [43] 0 0
Up to 7 days post dosing
Primary outcome [44] 0 0
Clinically significant abnormal change in percentage of Basophils
Timepoint [44] 0 0
Up to 7 days post dosing
Primary outcome [45] 0 0
Clinically significant abnormal change in Erythrocyte count
Timepoint [45] 0 0
Up to 7 days post dosing
Primary outcome [46] 0 0
Clinically significant abnormal change in Hemoglobin
Timepoint [46] 0 0
Up to 7 days post dosing
Primary outcome [47] 0 0
Clinically significant abnormal change in Hematocrit
Timepoint [47] 0 0
Up to 7 days post dosing
Primary outcome [48] 0 0
Clinically significant abnormal change in Platelets
Timepoint [48] 0 0
Up to 7 days post dosing
Primary outcome [49] 0 0
Clinically significant abnormal finding in Urine Occult Blood
Timepoint [49] 0 0
Up to 7 days post dosing
Primary outcome [50] 0 0
Clinically significant abnormal change in Urine Bilirubin
Timepoint [50] 0 0
Up to 7 days post dosing
Primary outcome [51] 0 0
Clinically significant abnormal change in Urine pH
Timepoint [51] 0 0
Up to 7 days post dosing
Primary outcome [52] 0 0
Clinically significant abnormal change in Urine Protein
Timepoint [52] 0 0
Up to 7 days post dosing
Primary outcome [53] 0 0
Clinically significant abnormal change in Urine Glucose
Timepoint [53] 0 0
Up to 7 days post dosing
Primary outcome [54] 0 0
Clinically significant abnormal change in Urine Specific gravity
Timepoint [54] 0 0
Up to 7 days post dosing
Primary outcome [55] 0 0
Clinically significant abnormal change in Urine Ketones
Timepoint [55] 0 0
Up to 7 days post dosing
Primary outcome [56] 0 0
Clinically significant abnormal change in Urobilinogen
Timepoint [56] 0 0
Up to 7 days post dosing
Primary outcome [57] 0 0
Clinically significant abnormal change in Urinary leukocyte
Timepoint [57] 0 0
Up to 7 days post dosing
Primary outcome [58] 0 0
Clinically significant abnormal change in Urine erythrocytes
Timepoint [58] 0 0
Up to 7 days post dosing
Primary outcome [59] 0 0
Clinically significant abnormal change in Urine Nitrites
Timepoint [59] 0 0
Up to 7 days post dosing
Primary outcome [60] 0 0
Clinically significant abnormal change in Prothrombin time (PT)
Timepoint [60] 0 0
Up to 7 days post dosing
Primary outcome [61] 0 0
Clinically significant abnormal change in Activated partial thromboplastin time (APTT)
Timepoint [61] 0 0
Up to 7 days post dosing
Primary outcome [62] 0 0
Clinically significant abnormal change in International normalized ratio (INR)
Timepoint [62] 0 0
Up to 7 days post dosing
Primary outcome [63] 0 0
Clinically significant abnormal change in Fibrinogen (FIB)
Timepoint [63] 0 0
Up to 7 days post dosing
Primary outcome [64] 0 0
Clinically significant abnormal change in Thrombin time (TT)
Timepoint [64] 0 0
Up to 7 days post dosing
Primary outcome [65] 0 0
Clinically significant abnormal in Feces colour
Timepoint [65] 0 0
Up to 7 days post dosing
Primary outcome [66] 0 0
Clinically significant abnormal in Feces properties
Timepoint [66] 0 0
Up to 7 days post dosing
Primary outcome [67] 0 0
Clinically significant abnormal in Fecal Red blood cell
Timepoint [67] 0 0
Up to 7 days post dosing
Primary outcome [68] 0 0
Clinically significant abnormal in Fecal White blood cell
Timepoint [68] 0 0
Up to 7 days post dosing
Primary outcome [69] 0 0
Clinically significant abnormal in Fecal Occult blood
Timepoint [69] 0 0
Up to 7 days post dosing
Secondary outcome [1] 0 0
AUC0-72 h: Area under the plasma concentration-time curve of CBP-174 from time 0 to 72h
Timepoint [1] 0 0
Up to 72 hours post dosing
Secondary outcome [2] 0 0
AUC0-8: Area under the plasma concentration-time curve of CBP-174 from time 0 to infinity
Timepoint [2] 0 0
Up to 72 hours post dosing
Secondary outcome [3] 0 0
Cmax: Maximum observed concentration
Timepoint [3] 0 0
Up to 72 hours post dosing
Secondary outcome [4] 0 0
Tmax: Time to maximum concentration;
Timepoint [4] 0 0
Up to 72 hours post dosing
Secondary outcome [5] 0 0
T1/2: Elimination half-life;
Timepoint [5] 0 0
Up to 72 hours post dosing
Secondary outcome [6] 0 0
?z: Terminal phase rate constant;
Timepoint [6] 0 0
Up to 72 hours post dosing
Secondary outcome [7] 0 0
CL/F: Apparent clearance;
Timepoint [7] 0 0
Up to 72 hours post dosing
Secondary outcome [8] 0 0
V/F: Apparent Volume;
Timepoint [8] 0 0
Up to 72 hours post dosing
Secondary outcome [9] 0 0
%AUCex: Percentage of AUC0-8 obtained by extrapolation
Timepoint [9] 0 0
Up to 72 hours post dosing

Eligibility
Key inclusion criteria
Subjects will be enrolled into the study only if they meet ALL of the following inclusion criteria:

1. Subjects are fully informed of the study, and are willing to participate in the study and sign the informed consent document prior to any procedure
2. Healthy male and female subjects, aged 18 to 55 years (both inclusive)
3. Body mass index is between 18 and 32 kg/m2 (both inclusive), the weight of male subjects = 50 kg, the weight of female subjects = 45 kg
4. Considered generally normal or abnormal with no clinical significance upon medical history, physical examination, vital signs, ECG, and clinical laboratory tests, as judged by the Investigator
5. Female subjects of child-bearing potential must agree to use highly effective contraceptive methods 1 month before the screening, during the entire study, and within 3 months after the end of this study, and have no egg donation plan within 3 months of study end. The male partner of a female subject must agree to use condoms during the screening, entire study, and within 3 months after the end of this study. Male subjects considered fertile must agree to not plan to father a child, donate sperm, and take effective contraceptive methods during the screening, entire study, and within 3 months after the end of this study. The female partner of male subjects must agree to use a highly effective method of female contraception (Section 9.8.3.2) during the screening, entire study, and within 3 months after the end of this study. Contraceptive requirements applies to subjects in same sex relationships for male and female subjects, female subjects of non child bearing potential or male subjects with female partners of non-childbearing potential.
6. Subjects who are able to communicate well with Investigators, as well as understand and adhere to the requirements of this study
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Subjects will be excluded from the study, if they meet ANY of the following criteria:

Subjects will be excluded from the study, if they meet ANY of the following criteria:

1. Subjects who have difficulties in venous blood collection or history of dizziness with blood or needles
2. Female subjects who have a positive pregnancy test or are breastfeeding
3. Subjects who have allergy/hypersensitivity history to any excipient of CBP-174 solution, or hypersensitivity to antihistamines, or severe allergies at the discretion of Investigator
4. Exposure to any other investigational medicinal product or any other clinical trial within 30 days or 5 times half-lives (whichever is longer) before dosing current study medication
5. Subjects who have a history of gastrointestinal (such as duodenal ulcer, alimentary tract hemorrhage, etc.), liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
6. Subjects who have a history of significant eye diseases (such as keratitis, and scleritis, etc.) or clinical significant eye signs (conjunctiva hyperemia, etc.)
7. Subjects who have a history of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD)
8. Subjects who have a history of sleep disorders within 2 years before the screening visit or score highly on the PSQI or ISI questionaire; or have a history of epilepsy or other seizure disorder

*Pittsburgh Sleep Quality Index (PSQI) = 8 or Insomnia Severity Index (ISI) = 8
9. Subjects who have the medical history of other significant diseases (including but not limited to pulmonary, cardiovascular, gastrointestinal, hematological endocrinological, immunological, dermatological, malignant diseases, mental and nervous systems, and other related diseases) or any other disease/ailment at the discretion of the Investigator
10. Subjects with any of the following clinical laboratory tests results at screening:

a Aspartate aminotransferase (AST) > 1.5 × the upper limit of normal (ULN)

b Alanine aminotransferase (ALT) > 1.5 × ULN

c Serum creatinine > 1.2 × ULN; or creatinine clearance < 60 mL/min (calculated by the Cockcroft-Gault)

*The clinical laboratory tests of hematology, blood biochemistry, or urinalysis could be allowed repeat once if Investigator considers it necessary
11. Subjects whose QTcF interval prolongation at screening (male: QTcF interval = 450 ms, female: QTcF interval = 470 ms)
12. Blood donation or blood loss more than 400 mL within 3 months before the screening visit
13. Subjects with a known history of drug abuse within 2 years before the screening visit; or positive drug abuse at screening
14. Weekly alcohol consumption of more than 14 units of alcohol (1 unit of alcohol = 360 mL of beer or 45 mL of spirit with the alcohol content of 40% or 150 mL of wine) in any week within the past 3 months before the screening visit; or intake of alcohol-containing products within 48 hours before the first dose, or cannot abstain from any alcohol product during the study, or positive breath alcohol test at screening or check-in (Day -1)
15. Smoking history (> 5 cigarettes per day) within 3 months before the screening visit, or cannot abstain from any tobacco products during the study, or positive urine nicotine test before randomization
16. Excessive drinking of tea, coffee, or caffeine-containing beverage (at least 8 cups per day, 1 cup = 250 mL) any day within 3 months before screening; intake of rich caffeine- or xanthine-containing food or drinks that may produce caffeine or xanthine after being metabolized (eg, coffee, tea, chocolate, cola drinks) within 48 hours before the first dose
17. Any marketed medication (prescription and nonprescription drugs) within 14 days before the first dose or within 5 times the elimination half-life or pharmacodynamic half-life of the medication (excluding oral contraceptives and low dose paracetamol at the discretion of the Investigator, or topical ointments at the discretion of the Investigator)
18. Administration of a Coronavirus Disease 2019 (COVID-19) vaccine in the past 14 days prior to dosing
19. Use of herbal medicines, dietary supplements and vitamin within 14 days before the first dose(permissible at the discretion of the Investigator)
20. Subjects who have a major surgery within 3 months before the first dose or who plan to undergo surgery during the study
21. Positive screening test for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C antibody
22. Subjects who are determined as not eligible to participate in this study by the Investigator

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/05/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
21/05/2022
Sample size
Target
Accrual to date
Final
74
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Nucleus Network Pty Ltd - Melbourne
Recruitment postcode(s) [1] 0 0
3004 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Connect Biopharma Australia Pty Ltd
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of CBP-174 after a single oral dose in healthy adult subjects.
Trial website
https://clinicaltrials.gov/study/NCT04811469
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Australia Connect
Address 0 0
Connect Biopharma Australia Pty Ltd
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04811469